Eli Lilly & Co. said its next-generation weight-loss shot did not increase overall heart risk in a new study, easing concerns as the treatment nears regulatory review, according to Bloomberg.
The result removes a lingering worry for the highly anticipated injection, which the company is developing for obesity and related conditions.
Eli Lilly Weight-Loss Shot Clears Heart-Risk Study
2026-07-23 10:45:43
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
